Short answer
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $192M (up 9.3% year over year) with net income of −$45M.
Q3 2025 key financials · XBRL
- Revenue
- $192M
- +9.3% YoY · +16.1% QoQ
- Net income
- −$45M
- −217.2% YoY · −300.5% QoQ
- Operating margin
- -31.4%
- EPS (diluted)
- −$0.80
- −215.9% YoY · −300.0% QoQ
Source: XBRL data from the SUPERNUS PHARMACEUTICALS, INC. (SUPN) Q3 2025 10-Q on SEC EDGAR. USD.
SUPERNUS PHARMACEUTICALS, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability or margin figures disclosed in section
- Best/worst performing product: ZURZUVAE with milestone payments up to $234M contingent on sales targets
- Cash impact from Sage Acquisition including sale of marketable securities to fund $66.9M per share contingent payments
- Near-term outlook includes contingent milestone payments through 2030 and potential Japan launch milestone by mid-2026
Risk Factors
- New tariff risk due to recent US tariffs on pharmaceuticals, possibly increasing import and vendor costs, currently assessing financial impact
- Legal risk materially updated: multiple litigation matters post-Sage acquisition, including securities class action, SEC subpoena, derivative litigation, and stockholder complaints in 2025
- Regulatory risk from 2025 Executive Orders aiming to lower US pharmaceutical prices, potentially reducing revenue for commercial products
- Market risk on ZURZUVAE commercialization: limited market acceptance risk due to boxed warning causing driving impairment, complicated reimbursement, and payer coverage restrictions
- Financial risk related to dependency on collaboration with Biogen for ZURZUVAE commercialization success, with uncertain revenue timing and levels to support business goals
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other SUPERNUS PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.